Patents Examined by Jacqueline Stone
  • Tumor necrosis factor formulations
    Patent number: 5215743
    Abstract: Compositions are described that are suitable for formulating cytokines, preferably tumor necrosis factor, that maintain their biological activities over a wide range of temperatures by, among other aspects, decreasing them sensitivity to agitation, and preventing oligomer and particulate matter formation.
    Type: Grant
    Filed: April 13, 1988
    Date of Patent: June 1, 1993
    Inventors: Maninder Singh, Flint Smith
  • Method for lowering blood cholesterol levels with granulocyte-macrophage colony stimulating factor
    Patent number: 5211947
    Abstract: A method for lowering the blood cholesterol levels in mammals and humans by administering GM-CSF is disclosed.
    Type: Grant
    Filed: December 16, 1988
    Date of Patent: May 18, 1993
    Assignee: Schering Corporation
    Inventors: Melvin D. Brannan, Hugh E. Black
  • Method for inhibiting heparanase activity
    Patent number: 5206223
    Abstract: Heparanase activity in a patient may be inhibited by administering an effective heparanase-inhibiting amount of heparin or an effective chemically modified derivative of heparin which inhibits heparanase activity. Such derivatives are preferably N-desulfated, N-acetylated heparin or O-desulfated, N-acetylated heparin. By means of this invention, allograft rejection may be prevented or delayed and autoimmune diseases such as arthritis may be alleviated and treated.
    Type: Grant
    Filed: September 17, 1990
    Date of Patent: April 27, 1993
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Israel Vlodavsky, Amiram Eldor, Yaakov Naparstek, Irun Cohen
  • Treatment of immobilized matrices for preparation of pharmaceutical and biological products with anti-microbial agents to remove pyrogen-producing organisms and pyrogens
    Patent number: 5202246
    Abstract: Disclosed are methods of inactivating pyrogen producing organisms and pyrogenic substances in immobilized solid matrices which are used in the production and/or purification of biomedical and pharmaceutical products and materials by contacting the solid matrices with pyrogen inactivating solutions.
    Type: Grant
    Filed: November 18, 1991
    Date of Patent: April 13, 1993
    Assignee: Armour Pharmaceutical Company
    Inventors: Robert Kruse, Sudhish Chandra, Fred Feldman
  • Methods of reducing glial scar formation and promoting axon and blood vessel growth and/or regeneration through the use of activated immature astrocytes
    Patent number: 5202120
    Abstract: The present invention relates to "activated" immature astrocytes and the methods of utilizing the activated immature astrocytes as a means for promotingPursuant to the provisions of 35 U.S.C. .sctn.202(c), it is hereby acknowledged that the Government has certain rights in this invention, which was made in part with funds from the National Eye Institute of the National Institutes of Health.
    Type: Grant
    Filed: October 27, 1989
    Date of Patent: April 13, 1993
    Assignee: Case Western Reserve University
    Inventors: Jerry Silver, George M. Smith, James W. Jacobberger
  • Thrombolytic compositions
    Patent number: 5202121
    Abstract: A thrombolytically active composition comprising in combination a modified tissue-type plasminogen activator (t-PA) as a major component and a normal human t-PA, Streptokinase or human urokinase as a minor component in a pharmaceutically acceptable excipient;a method of treating a thrombotic disorder; anda medicinal kit or package for use in treating thrombotic disorders.
    Type: Grant
    Filed: December 29, 1989
    Date of Patent: April 13, 1993
    Assignee: Kabigen AB
    Inventors: Gunnar Pohl, Christer Mattsson
  • Oral bilirubin therapy
    Patent number: 5200181
    Abstract: Levels of bilirubin in mammalian serum are controlled by administering to the mammalian intestinal tract a substance (a "bilirubin deactivator") that converts unconjugated bilirubin into nontoxic, physiologically compatible products, thereby reducing reabsorption of unconjugated bilirubin in enterohepatic circulation. Useful bilirubin deactivators include those which specifically adsorb the bilirubin and are excreted, and "bilirubin conversion enzymes", i.e., enzymes that operate on the unconjugated bilirubin substrate to yield products that are physiologically compatible in that they are not reabsorbed, or, if reabsorbed, they are nontoxic in the blood stream.
    Type: Grant
    Filed: October 1, 1990
    Date of Patent: April 6, 1993
    Assignee: Massachusetts Institute of Technology
    Inventors: Paul J. Soltys, Claudy J. P. Mullon, Robert S. Langer
  • Recombinant bile salt activated lipases
    Patent number: 5200183
    Abstract: The complete structure of human milk BAL cDNA is disclosed. The nucleotide sequences of the cDNA inserts of two clones overlap and together contain 2951 base pairs of BAL cDNA which codes for an open reading frame of 742 amino acid residues between initiation and termination codons. There is a putative signal sequence of 20 residues which is followed by a 61-amino-terminal sequence of BAL. The cDNA sequence also contains a 678-base 5'-untranslated sequence, a 97-base 3'-untranslated region, and a 14-base poly(A) tail. The deduced BAL protein structure contains in the carboxyl-terminal region fourteen repeating unis of 11 amino acids each. The repeating units have the basic structure of Pro-Val-Pro-Pro-Thr-Gly-Asp-Ser-Gly-Ala-Pro-, with only minor substitutions.
    Type: Grant
    Filed: June 12, 1990
    Date of Patent: April 6, 1993
    Assignee: Oklahoma Medical Research Foundation
    Inventors: Jordan J. N. Tang, Chi-Sun Wang
  • Methods of treating pancytopenia and AIDS by co-administering EPO and colony stimulating factors
    Patent number: 5198417
    Abstract: Disclosed herein is the treatment of patients suffering from AIDS-type disease with erythropoietin alone or together with a colony stimulating factor, and/or an anti-viral agent and/or IL-2.
    Type: Grant
    Filed: November 7, 1989
    Date of Patent: March 30, 1993
    Assignee: Genetics Institute, Inc.
    Inventor: Robert E. Donahue
  • Use of arginase to control nitric oxide formation
    Patent number: 5196195
    Abstract: Reducing plasma levels of endogenous arginine by parenteral administration of arginine depleting agent reduces nitric oxide levels and results in blood pressure increase. Preferably arginase is administered intravenously to raise blood pressure. The arginase can be administered in conjunction with arginine antagonists to potentiate the effect of these. Duration of action and avoidance of antigenicity may be obtained by use in conjunction with a carrier or modifier.
    Type: Grant
    Filed: March 27, 1990
    Date of Patent: March 23, 1993
    Assignee: Cornell Research Foundation, Inc.
    Inventor: Owen W. Griffith
  • Acellular red blood cell substitute
    Patent number: 5194590
    Abstract: An acellular red blood cell substitute which comprises an essentially tetramer-free, substantially stroma-free, cross-linked, polymerized, pyridoxylated hemoglobin and a nontoxic, pharmaceutically acceptable carrier, its uses and a process for preparing said acellular red blood cell substitute.
    Type: Grant
    Filed: November 21, 1990
    Date of Patent: March 16, 1993
    Assignee: Northfield Laboratories, Inc.
    Inventors: Lakshman R. Sehgal, Richard E. De Woskin, Gerald S. Moss, Steven A. Gould, Arthur L. Rosen, Hansa Sehgal
  • Method to produce recombinant proteins using an expression vector comprising transcriptional and translational activating sequences
    Patent number: 5192669
    Abstract: The present invention is composed of novel recombinant DNA expression vectors which contain a transcriptional activating sequence, a translational activating sequence and a DNA sequence coding for a functional polypeptide, especially bovine growth hormone. The aforementioned translational activating sequences contain a ribosome binding site and are designed to provide high level expression of DNA that codes for virtually any functional polypeptide. The invention further provides transformed microbial host cells capable of producing bovine growth hormone and other functional polypeptides at high levels.
    Type: Grant
    Filed: August 13, 1991
    Date of Patent: March 9, 1993
    Assignee: Eli Lilly and Company
    Inventors: Brigitte E. Schoner, Ronald G. Schoner
  • Methods for thrombolytic therapy
    Patent number: 5188830
    Abstract: Certain Factor XIIIa inhibitor compounds have been discovered which have been found to be useful in the lysis of blood clots and thus adaptable for administration in thrombolytic therapy either alone or together with plasminogen activator.
    Type: Grant
    Filed: April 2, 1990
    Date of Patent: February 23, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Joseph G. Atkinson, David A. Claremon, John J. Baldwin, Paul A. Friedman, David C. Remy, Andrew M. Stern
  • Methods for thrombolytic therapy
    Patent number: 5185149
    Abstract: Certain Factor XIIIa inhibitor compounds have been discovered which have been found to be useful in the lysis of blood clots and thus adaptable for administration in thrombolytic therapy either alone or together with plasminogen activator.
    Type: Grant
    Filed: April 2, 1990
    Date of Patent: February 9, 1993
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Paul A. Friedman, Andrew M. Stern
  • Platelet membrane microvesicles
    Patent number: 5185160
    Abstract: A heat-treated, viral-inactivated platelet membrane microparticle fraction is provided. The microparticles may be prepared from outdated platelets. The microparticle fraction is substantially free of platelet ghosts and may be used as a pharmaceutical preparation in transfusions.
    Type: Grant
    Filed: April 14, 1989
    Date of Patent: February 9, 1993
    Assignee: PRP, Inc.
    Inventor: Francis C. Chao
  • Intraocular anticoagulant including antithrombin III and method of administration
    Patent number: 5182259
    Abstract: An intraocular anticoagulant including antithrombin III is applicable as an injection into the ocular chamber of the eye at the time of cataract surgery, intraocular lens implant surgery, and other ocular surgeries. The anticoagulant prevents fibrin deposits from forming on the intraocular lens surface after surgery and avoids postoperative viscoelastic material inducing transient elevation in intraocular pressure.
    Type: Grant
    Filed: July 25, 1989
    Date of Patent: January 26, 1993
    Inventor: Kiyoshi Kita
  • Method for the treatment of bleeding disorders
    Patent number: 5180583
    Abstract: A method for treating patients suffering from bleeding disorders not caused by clotting factor defects or clotting factor inhibitors, as well as a novel composition for use in treating bleeding disorders as disclosed. The method includes administering to a patient a composition comprising an effective haemostatic amount of factor VIIa, and is particularly effective in treating patients suffering from thrombocytopenia and von Willebrand's disease, as well as other platelet disorders. A composition suitable for use in treating such bleeding disorders comprises purified factor VIIa in a concentration of at least 25 .mu.g/ ml.
    Type: Grant
    Filed: March 8, 1991
    Date of Patent: January 19, 1993
    Inventor: Ulla K. E. Hedner
  • Pharmaceutical compositions comprising selected lactobacillus strains
    Patent number: 5176911
    Abstract: Topical pharmaceutical compositions, suited for the use in gynecology and urology, comprise as active principles selected Lactobacillus strains isolated from vaginal or urologic habitat of asymptomatic patients.
    Type: Grant
    Filed: August 2, 1989
    Date of Patent: January 5, 1993
    Assignees: Universita Cattolica del Sacro Cuore, Dr. A. Tosi Farmaceutici S.r.l.
    Inventors: Silvana Tosi, Giancarla Dondi, Vittorio Bottazzi, Franco Dellaglio, Lorenzo Morelli
  • Pharmaceutical composition having thrombolytic activity
    Patent number: 5174994
    Abstract: Plasminogen activators of the tissue-type and plasminogen activators of the urokinase-type appear to have a synergistic action in vivo when administered together as thrombolytic agents. Use in pharmaceutical compositions and in methods for the preparation and use thereof are set forth.
    Type: Grant
    Filed: July 21, 1989
    Date of Patent: December 29, 1992
    Assignee: Leuven Research & Development VZW
    Inventor: Desire J. Collen
  • Preparation of virus-free antibodies
    Patent number: 5159064
    Abstract: Antibodies, including monoclonal antibodies (Mabs), can be made substantially free of infectious viruses by storing them in a liquid state at conditions of pH, temperature and time sufficient to inactive substantially all infectious viruses. Preferred inactivation methods involve use of a pH equal to or less than about 4.0 at a temperature of at least about 5.degree. C. for at least about 16 hours.
    Type: Grant
    Filed: January 29, 1990
    Date of Patent: October 27, 1992
    Assignee: Miles Inc.
    Inventors: Gautam Mitra, Milton M. Mozen